https://mararating.com/report/apalutamide-for-treating-high-risk-hormone-relapsed-nonmetastatic-prostate-cancer-as-of-october-2021-market-access-risk-assessment/
Apalutamide / erleada for treating high-risk hormone-relapsed nonmetastatic prostate cancer as of...
Sep 28, 2026 - As of October 2021, MARA's assessment finds Apalutamide / Erleada's reimbursement risk concentrated in care pathway integration.
high riskprostate canceras ofapalutamideerleada
https://cris.unibo.it/handle/11585/773722
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
for theprostate cancerenzalutamidetreatmentnonmetastatic